Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Descrição
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
PDF) Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole
Introduction - Clinical Review Report: Brexpiprazole (Rexulti) - NCBI Bookshelf
Rexulti 1 Mg, Antipsychotic - 28 Tablets
ex9902009.jpg
PDF) Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole
1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals
Rexulti Approved by FDA for Major Depressive Disorder and Schizophrenia
PDF] Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.
Full article: In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals
Rexulti.PDF
de
por adulto (o preço varia de acordo com o tamanho do grupo)
